26. The method of claim 25 in which said kappa opioid receptor agonist exhibits little, if any, potential for producing side effects associated with centrally acting kappa opiate receptor agonists.

27. The method of claim 25 in which said administration is topical.

28. The method of claim 25 in which said administration is systemic.

29. The method of claim 25 in which said administration is parenteral.

30. The method of claim 25 in which said administration is rectal.

31. The method of claim 25 in which said agonist is administered in an amount between about 0.05 mg and 500 mg.

32. The method of claim 31 in which said agonist is administered in an amount between about 1 mg and 200 mg.

33. A composition comprising a kappa opiate receptor agonist, or pharmaceutically acceptable salt thereof, that is substantially devoid of central nervous system effects, in a pharmaceutically acceptable carrier.

REMARKS

The claims are 1-18. Claims 1-18 are herein withdrawn from consideration. New claims 25-33 are added herein. Therefore, the claims are 25-33. Consideration and allowance of all claims are respectfully requested in view of the following remarks.

New claims 25-33 have been added to more particularly point out and distinctly claim subject matter which the Applicants regard as their invention. These new claims are supported by the specification as filed, and Applicants believe that no new matter has been added.